Loading...

AMAG Pharmaceuticals

Nasdaq:AMAG
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AMAG
Nasdaq
$385M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • AMAG Pharmaceuticals has significant price volatility in the past 3 months.
AMAG Share Price and Events
7 Day Returns
1.8%
NasdaqGS:AMAG
-5.7%
US Biotechs
-3.9%
US Market
1 Year Returns
-53.8%
NasdaqGS:AMAG
-7.9%
US Biotechs
1.4%
US Market
AMAG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AMAG Pharmaceuticals (AMAG) 1.8% -9.4% -31.8% -53.8% -37.9% -36%
US Biotechs -5.7% -8.7% -6.4% -7.9% 5.5% 10.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • AMAG underperformed the Biotechs industry which returned -7.9% over the past year.
  • AMAG underperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
AMAG
Industry
5yr Volatility vs Market
Related Companies

AMAG Value

 Is AMAG Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AMAG Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AMAG Pharmaceuticals.

NasdaqGS:AMAG Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:AMAG
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.383 (1 + (1- 21%) (71.09%))
1.777
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.78
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.777 * 5.96%)
13.32%

Discounted Cash Flow Calculation for NasdaqGS:AMAG using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AMAG Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:AMAG DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 13.32%)
2019 -39.60 Analyst x3 -34.95
2020 -68.07 Analyst x3 -53.01
2021 12.85 Analyst x2 8.83
2022 52.75 Analyst x2 31.99
2023 55.40 Analyst x1 29.65
2024 57.76 Est @ 4.25% 27.27
2025 59.95 Est @ 3.8% 24.98
2026 62.03 Est @ 3.48% 22.81
2027 64.05 Est @ 3.25% 20.78
2028 66.03 Est @ 3.1% 18.91
Present value of next 10 years cash flows $97.28
NasdaqGS:AMAG DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $66.03 × (1 + 2.73%) ÷ (13.32% – 2.73%)
$640.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $640.54 ÷ (1 + 13.32%)10
$183.44
NasdaqGS:AMAG Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $97.28 + $183.44
$280.71
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $280.71 / 33.77
$8.31
NasdaqGS:AMAG Discount to Share Price
Calculation Result
Value per share (USD) From above. $8.31
Current discount Discount to share price of $11.39
= -1 x ($11.39 - $8.31) / $8.31
-37%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of AMAG Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AMAG Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AMAG Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:AMAG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-6.77
NasdaqGS:AMAG Share Price ** NasdaqGS (2019-05-15) in USD $11.39
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.35x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AMAG Pharmaceuticals.

NasdaqGS:AMAG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AMAG Share Price ÷ EPS (both in USD)

= 11.39 ÷ -6.77

-1.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AMAG Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • AMAG Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AMAG Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:AMAG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
58.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.15x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AMAG Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AMAG Pharmaceuticals's assets?
Raw Data
NasdaqGS:AMAG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $18.22
NasdaqGS:AMAG Share Price * NasdaqGS (2019-05-15) in USD $11.39
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.11x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:AMAG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AMAG Share Price ÷ Book Value per Share (both in USD)

= 11.39 ÷ 18.22

0.63x

* Primary Listing of AMAG Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AMAG Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess AMAG Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AMAG Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AMAG Future Performance

 How is AMAG Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AMAG Pharmaceuticals expected to grow at an attractive rate?
  • AMAG Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • AMAG Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • AMAG Pharmaceuticals's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:AMAG Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:AMAG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 58.9%
NasdaqGS:AMAG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 5.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:AMAG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:AMAG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 450 140 23 6
2022-12-31 463 85 15 7
2021-12-31 414 33 -26 7
2020-12-31 368 -75 -123 8
2019-12-31 369 -14 -199 8
NasdaqGS:AMAG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 432 -75 -233
2018-12-31 474 61 -169
2018-09-30 514 155 -148
2018-06-30 516 136 -239
2018-03-31 501 167 -227
2017-12-31 496 107 -205
2017-09-30 519 99 -216
2017-06-30 538 131 -45
2017-03-31 535 205 -31
2016-12-31 432 246 2
2016-09-30 489 222 15
2016-06-30 442 135 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AMAG Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • AMAG Pharmaceuticals's revenue is expected to grow by 5.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:AMAG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from AMAG Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMAG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.14 0.81 -0.53 2.00
2022-12-31 -0.02 0.77 -1.22 3.00
2021-12-31 -1.37 -0.76 -2.42 3.00
2020-12-31 -3.83 -2.76 -4.97 5.00
2019-12-31 -5.97 -5.49 -6.70 4.00
NasdaqGS:AMAG Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -6.77
2018-12-31 -4.92
2018-09-30 -4.29
2018-06-30 -6.89
2018-03-31 -6.52
2017-12-31 -5.88
2017-09-30 -6.22
2017-06-30 -1.29
2017-03-31 -0.90
2016-12-31 0.06
2016-09-30 0.44
2016-06-30 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AMAG Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AMAG Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AMAG Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AMAG Past Performance

  How has AMAG Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AMAG Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AMAG Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AMAG Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AMAG Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AMAG Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AMAG Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMAG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 432.42 -233.32 279.30 18.46
2018-12-31 474.00 -169.34 277.42 16.95
2018-09-30 514.41 -147.86 270.17 16.96
2018-06-30 516.50 -238.89 259.61 17.82
2018-03-31 500.62 -227.33 251.06 18.83
2017-12-31 495.77 -205.15 225.84 19.06
2017-09-30 518.83 -216.45 223.60 18.75
2017-06-30 538.29 -44.54 215.23 17.42
2017-03-31 535.33 -30.88 213.65 16.06
2016-12-31 432.49 2.09 143.79 15.38
2016-09-30 489.24 15.28 217.72 24.39
2016-06-30 441.61 -21.51 207.46 14.12
2016-03-31 438.07 12.35 184.64 13.60
2015-12-31 418.28 32.78 156.04 13.98
2015-09-30 362.79 168.59 131.20 2.33
2015-06-30 292.14 190.63 102.61 11.12
2015-03-31 193.05 155.82 85.75 10.35
2014-12-31 124.38 135.82 72.94 10.89
2014-09-30 92.84 -10.85 62.09 9.41
2014-06-30 88.96 -12.45 60.57 9.58
2014-03-31 83.81 -12.81 58.29 9.77
2013-12-31 80.86 -9.60 54.99 11.57
2013-09-30 80.29 -9.63 52.80 11.93
2013-06-30 76.42 -13.46 51.81 12.78
2013-03-31 87.78 -8.23 53.30 13.31
2012-12-31 85.38 -16.75 53.07 14.23
2012-09-30 79.14 -31.65 51.12 14.47
2012-06-30 78.95 -44.31 56.19 -5.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AMAG Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AMAG Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AMAG Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AMAG Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AMAG Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AMAG Health

 How is AMAG Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AMAG Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AMAG Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AMAG Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AMAG Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AMAG Pharmaceuticals Company Filings, last reported 1 month ago.

NasdaqGS:AMAG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 614.72 273.43 266.51
2018-12-31 746.66 283.21 394.17
2018-09-30 762.25 279.38 427.53
2018-06-30 726.90 742.54 351.17
2018-03-31 740.00 738.56 370.56
2017-12-31 790.24 734.68 299.45
2017-09-30 800.31 755.42 394.10
2017-06-30 947.45 769.76 399.21
2017-03-31 924.09 985.35 558.40
2016-12-31 934.39 986.52 579.09
2016-09-30 937.95 987.81 614.07
2016-06-30 916.17 989.11 546.47
2016-03-31 922.97 990.48 480.21
2015-12-31 932.26 991.92 466.33
2015-09-30 919.96 1,005.16 442.87
2015-06-30 712.98 483.20 398.41
2015-03-31 671.18 489.24 361.14
2014-12-31 459.95 495.35 144.19
2014-09-30 196.98 165.78 386.24
2014-06-30 192.99 164.13 386.47
2014-03-31 191.10 162.56 385.47
2013-12-31 172.41 0.00 213.79
2013-09-30 174.25 0.00 213.54
2013-06-30 171.08 0.00 212.41
2013-03-31 171.25 0.00 217.07
2012-12-31 172.80 0.00 227.04
2012-09-30 174.70 0.00 210.84
2012-06-30 176.39 0.00 207.25
  • AMAG Pharmaceuticals's level of debt (44.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (85.1% vs 44.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AMAG Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • AMAG Pharmaceuticals has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 41.6% each year.
X
Financial health checks
We assess AMAG Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AMAG Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AMAG Dividends

 What is AMAG Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AMAG Pharmaceuticals dividends.
If you bought $2,000 of AMAG Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AMAG Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AMAG Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:AMAG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:AMAG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AMAG Pharmaceuticals has not reported any payouts.
  • Unable to verify if AMAG Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AMAG Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AMAG Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AMAG Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AMAG Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AMAG Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AMAG Management

 What is the CEO of AMAG Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Heiden
COMPENSATION $4,966,215
AGE 58
TENURE AS CEO 7 years
CEO Bio

Dr. William K. Heiden, also known as Bill, has been the Chief Executive Officer of AMAG Pharmaceuticals, Inc. since May 14, 2012 and serves as its President. Dr. Heiden serves as the Managing Director of Vitruvian Pharmaceuticals. Dr. Heiden served as the President of AMAG Pharmaceuticals, Inc. since May 14, 2012 until April 1, 2015. Dr. Heiden served as the Chief Executive Officer and President of GTC Biotherapeutics, Inc., since June 2010. He served as the President and Chief Executive Officer for Elixir Pharmaceuticals, Inc. from September 2004 to December 2008. Dr. Heiden joined Praecis Pharmaceuticals Inc. in May 9, 2002 and served as its President and Chief Operating Officer from May 9, 2002 to September 3, 2004. He joined Schering-Plough Corporation in 1987 and served as Vice President of Schering's Oncology/Biotech business unit. Mr. Heiden is an experienced pharmaceutical and biotechnology executive. From 1987 to 2002, he progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.). He spent 15 years at Schering Plough where he held positions of increasing responsibility including Managing Director of a number of businesses in Europe and Canada, Vice President of Schering’s U.S. cardiovascular business unit. From April 1998 to July 1999, Dr. Heiden served as Vice President of marketing and sales at Key-Acute Coronary Syndromes, (now Millennium Pharmaceuticals, Inc.). He served as Schering's Director of Managed Health Care from 1996 to 1998, with responsibility for all Schering products within Managed Care for a twelve state region. From 1988 to 1996, he held a variety of management roles in Schering's International Division. He served as General Manager for Schering's business in the BeNeLux (Belgium, Netherlands and Luxembourg), Head of prescription product marketing at Schering Canada and General Manager for Schering Belgium. He served as the Chairman of the Board of rEVO Biologics since June 2010. He has been a Director of Atara Biotherapeutics, Inc. since November 23, 2015. He has been a Director of AMAG Pharmaceuticals, Inc since May 14, 2012. He served as a Director of rEVO Biologics since October 1, 2009. He served as Director of LFB S.A., and LFB Biotechnologies. He served as Director of Elixir Pharmaceuticals, Inc. since September 2004 and ConjuChem Biotechnologies, Inc., since January 2008. He is a member of the Duke University Healthcare Advisory Club. Dr. Heiden holds an B.A. in Business Administration from the University of Florida, his M.I.M. from the University of Louvain, Louvain, Belgium and an MBA from the Johnson School of Management, Cornell University. He holds BS from University of Florida. He holds MA and MS from University of Louvain.

CEO Compensation
  • Bill's compensation has increased whilst company is loss making.
  • Bill's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AMAG Pharmaceuticals management team in years:

3.1
Average Tenure
51
Average Age
  • The tenure for the AMAG Pharmaceuticals management team is about average.
Management Team

Bill Heiden

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
58
TENURE
7 yrs

Ted Myles

TITLE
Executive VP
COMPENSATION
$2M
AGE
46
TENURE
3.1 yrs

Julie Krop

TITLE
Executive VP of Development & Chief Medical Officer
COMPENSATION
$2M
AGE
52
TENURE
3.9 yrs

James Butcher

TITLE
Executive VP & Chief Business Officer
COMPENSATION
$2M
AGE
51
TENURE
1.1 yrs

Linda Lennox

TITLE
Vice President of Investor Relations & Corporate Communications

Joseph Vittiglio

TITLE
Executive VP of Legal Affairs and Quality
COMPENSATION
$1M
AGE
46
TENURE
3.8 yrs

Tracy Berns

TITLE
Chief Compliance Officer
TENURE
1.7 yrs

Amit Verma

TITLE
Vice President of Marketing
TENURE
5.8 yrs

Elizabeth Bolgiano

TITLE
Executive VP & Chief Human Resources Officer
AGE
56
TENURE
1.4 yrs

Tony Casciano

TITLE
Chief Commercial Officer
AGE
41
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the AMAG Pharmaceuticals board of directors in years:

5.4
Average Tenure
62
Average Age
  • The tenure for the AMAG Pharmaceuticals board of directors is about average.
Board of Directors

Gino Santini

TITLE
Chairman
COMPENSATION
$283K
AGE
61
TENURE
5.1 yrs

Bill Heiden

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
58
TENURE
7 yrs

Davey Scoon

TITLE
Director
COMPENSATION
$255K
AGE
71
TENURE
12.4 yrs

Lesley Cooper

TITLE
Director
COMPENSATION
$245K
AGE
57
TENURE
9.4 yrs

John Fallon

TITLE
Director
COMPENSATION
$247K
AGE
70
TENURE
4.7 yrs

Rob Perez

TITLE
Director
COMPENSATION
$230K
AGE
54
TENURE
10.3 yrs

Barbara Deptula

TITLE
Director
COMPENSATION
$241K
AGE
63
TENURE
5.7 yrs

Jim Sulat

TITLE
Director
COMPENSATION
$238K
AGE
68
TENURE
5.1 yrs

Kathrine O’Brien

TITLE
Independent Director
AGE
55
TENURE
0.1 yrs

Anne Phillips

TITLE
Independent Director
AGE
64
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by AMAG Pharmaceuticals insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. May 19 Buy William Heiden Individual 09. May 19 09. May 19 10,000 $10.70 $107,000
09. May 19 Buy Elizabeth Bolgiano Individual 09. May 19 09. May 19 5,000 $10.93 $54,650
X
Management checks
We assess AMAG Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AMAG Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AMAG News

Simply Wall St News

Should You Worry About AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) CEO Pay?

View our latest analysis for AMAG Pharmaceuticals How Does Bill Heiden's Compensation Compare With Similar Sized Companies? … Thus we can conclude that Bill Heiden receives more in total compensation than the median of a group of companies in the same market, and of similar size to AMAG Pharmaceuticals, Inc.. … We compared the total CEO remuneration paid by AMAG Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

Volatility 101: Should AMAG Pharmaceuticals (NASDAQ:AMAG) Shares Have Dropped 41%?

AMAG Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last half decade, AMAG Pharmaceuticals saw its revenue increase by 30% per year. … So you might argue the AMAG Pharmaceuticals should get more credit for its rather impressive revenue growth over the period.

Simply Wall St -

Does AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) CEO Salary Reflect Performance?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Bill Heiden's Compensation Compare With Similar Sized Companies. … has a market cap of US$596m, and is paying total annual CEO compensation of US$4.3m.

Simply Wall St -

Estimating The Intrinsic Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

How far off is AMAG Pharmaceuticals Inc (NASDAQ:AMAG) from its intrinsic value? … by taking the expected future cash flows and discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Does AMAG Pharmaceuticals Inc's (NASDAQ:AMAG) CEO Salary Reflect Performance?

Leading AMAG Pharmaceuticals Inc (NASDAQ:AMAG) as the CEO, Bill Heiden took the company to a valuation of US$858.37m. … Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … CEOs leading companies of similar size and profitability

Simply Wall St -

Calculating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

In this article I am going to calculate the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG). … by taking the expected future cash flows and discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

A Look At The Intrinsic Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

In this article I am going to calculate the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) by taking the expected future cash flows and discounting them to today's value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF ($, Millions) $88.89 $72.48 $94.26 $113.72 $136.19 Source Analyst x3 Analyst x3 Analyst x2 Analyst x2 Analyst x2 Present Value Discounted @ 17.53% $75.63 $52.47 $58.06 $59.60 $60.73 Present Value of 5-year Cash Flow (PVCF)= $306 We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = $136 × (1 + 2.5%) ÷ (17.5% – 2.5%) = $927 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = $927 / ( 1 + 17.5%)5 = $413 The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is $720.

Simply Wall St -

What Are Analysts Saying About The Future Of AMAG Pharmaceuticals Inc's (NASDAQ:AMAG)?

After AMAG Pharmaceuticals Inc's (NASDAQ:AMAG) earnings announcement in December 2017, it seems that analyst forecasts are fairly optimistic, as a 22.78% increase in profits is expected in the upcoming year, relative to the past 5-year average growth rate of 4.62%. … To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line. … NasdaqGS:AMAG Future Profit Mar 9th 18 This results in an annual growth rate of 47.09% based on the most recent earnings level of -US$199.23M to the final forecast of -US$342.79M by 2021.

Simply Wall St -

Loss-Making AMAG Pharmaceuticals Inc (NASDAQ:AMAG) Expected To Breakeven

Many investors are wondering the rate at which AMAG will turn a profit, with the big question being “when will the company breakeven?” Below I will provide a high-level summary of the industry analysts’ expectations for AMAG. … Check out our latest analysis for AMAG Pharmaceuticals AMAG is bordering on breakeven, according to analysts. … Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on AMAG Pharmaceuticals’s board and the CEO’s back ground.

Simply Wall St -

What Does AMAG Pharmaceuticals Inc's (NASDAQ:AMAG) Ownership Structure Look Like?

A company's ownership structure is often linked to its share performance in both the long- and short-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital.

Simply Wall St -

AMAG Company Info

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company’s products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Details
Name: AMAG Pharmaceuticals, Inc.
AMAG
Exchange: NasdaqGS
Founded: 1981
$384,605,435
33,766,939
Website: http://www.amagpharma.com
Address: AMAG Pharmaceuticals, Inc.
1100 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AMAG Common Stock Nasdaq Global Select US USD 11. Jun 1986
DB AMU Common Stock Deutsche Boerse AG DE EUR 11. Jun 1986
Number of employees
Current staff
Staff numbers
467
AMAG Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 01:58
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.